Cargando…

PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review

Detalles Bibliográficos
Autores principales:	Handelsman, Yehuda, Lepor, Norman E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Contemporary Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064883/ https://www.ncbi.nlm.nih.gov/pubmed/29934421 http://dx.doi.org/10.1161/JAHA.118.008953

Ejemplares similares

Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
por: Wilkinson, Michael J., et al.
Publicado: (2023)

Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review
por: Claessen, Bimmer E., et al.
Publicado: (2020)

Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
por: Punch, Emily, et al.
Publicado: (2022)

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
por: Jia, Xiaoming, et al.
Publicado: (2022)

Maternal Obesity and Diabetes Mellitus as Risk Factors for Congenital Heart Disease in the Offspring
por: Helle, Emmi, et al.
Publicado: (2020)

Diagnosis and Management of Cardiovascular Disease in Advanced and End‐Stage Renal Disease
por: Bhatti, Navdeep K., et al.
Publicado: (2016)

Management of Cardiovascular Risk Factors in Adults With Congenital Heart Disease
por: Lui, George K., et al.
Publicado: (2014)

Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk
por: Behr, Paulo Eduardo Ballvé, et al.
Publicado: (2018)

Taking Diabetes to Heart—Deregulation of Myocardial Lipid Metabolism in Diabetic Cardiomyopathy
por: Bayeva, Marina, et al.
Publicado: (2013)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

Lipid Levels and Use of Lipid-Lowering Drugs for Patients in Pharmacist-Managed Lipid Clinics Versus Usual Care in 2 VA Medical Centers
por: Mazzolini, Timothy A., et al.
Publicado: (2005)

What Is the Best Mix of Population‐Wide and High‐Risk Targeted Strategies of Primary Stroke and Cardiovascular Disease Prevention?
por: Feigin, Valery L., et al.
Publicado: (2020)

Contemporary Cardiovascular Imaging Methods for the Assessment of At‐Risk Myocardium
por: Wince, W. Benjamin, et al.
Publicado: (2014)

Hypertensive Disorders of Pregnancy and Future Maternal Cardiovascular Risk
por: Ying, Wendy, et al.
Publicado: (2018)

Assessment of Clinical Pharmacist Management of Lipid-Lowering Therapy in a Primary Care Setting
por: Till, Traywick L, et al.
Publicado: (2003)

Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
por: Ciccarelli, Giovanni, et al.
Publicado: (2018)

Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis
por: Zhao, Liming, et al.
Publicado: (2023)

Migraine Headache: An Under‐Appreciated Risk Factor for Cardiovascular Disease in Women
por: Elgendy, Islam Y., et al.
Publicado: (2019)

Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection
por: Titanji, Boghuma, et al.
Publicado: (2020)

Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency
por: Tarasov, Kirill, et al.
Publicado: (2014)

Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease
por: Hung, Szu‐Chun, et al.
Publicado: (2017)

Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management
por: Waiz, Mohd, et al.
Publicado: (2022)

Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC()
por: Bloomgarden, Zachary, et al.
Publicado: (2020)

Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy
por: Tietjens, Jeremy R., et al.
Publicado: (2018)

SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
por: Lam, Carolyn S. P., et al.
Publicado: (2019)

Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes
por: Myers, Kelly D., et al.
Publicado: (2019)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
por: Peng, Jia, et al.
Publicado: (2021)

Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects
por: Duprez, Daniel A, et al.
Publicado: (2020)

Treatment, Behavioral, and Psychosocial Components of Cardiovascular Disease Risk Among Survivors of Childhood and Young Adult Cancer
por: Berkman, Amy M., et al.
Publicado: (2015)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

Imaging Cardiovascular Calcification
por: Wang, Ying, et al.
Publicado: (2018)

Longitudinal Assessment of a Diabetes Care Management System in an Integrated Health Network
por: Larsen, David L., et al.
Publicado: (2003)

PCSK9 inhibitors: A new era of lipid lowering therapy
por: Chaudhary, Rahul, et al.
Publicado: (2017)

The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
por: Lu, Fengyuan, et al.
Publicado: (2023)

Gene Therapy to Treat Cardiovascular Disease
por: Wolfram, Julie A., et al.
Publicado: (2013)

Role of Heme in Cardiovascular Physiology and Disease
por: Sawicki, Konrad Teodor, et al.
Publicado: (2015)

American‐Style Football and Cardiovascular Health
por: Kim, Jonathan H., et al.
Publicado: (2018)

Impact of Electronic Cigarettes on the Cardiovascular System
por: Qasim, Hanan, et al.
Publicado: (2017)

The Emerging Role of Irisin in Cardiovascular Diseases
por: Fu, Jinjuan, et al.
Publicado: (2021)

Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations
por: Orringer, Carl E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cs92pk2g27buv9r1h5amlqsj2s